On July 17, 2017 Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reported that it has entered into a commercial license and supply agreement with Amgen, granting rights to use Ligand’s Captisol technology in the formulation of AMG 330 (Press release, Ligand, JUL 17, 2017, View Source [SID1234519812]). Captisol is a patent protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. AMG 330 is an anti-CD33 x anti-CD3 (BiTE) bispecific antibody construct. It is being investigated as a treatment for acute myeloid leukemia by Amgen. Schedule your 30 min Free 1stOncology Demo! This license agreement replaces the prior research agreement which allowed Amgen to evaluate AMG 330 with Captisol in preclinical and early clinical studies. Under this new commercial license agreement, Amgen receives exclusive worldwide rights to combine Captisol with AMG 330 for use in humans for a wide variety of therapeutic indications. In addition to an upfront payment, Ligand is entitled to potential milestone payments, royalties and revenue from future sales of AMG 330 formulated using Captisol.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"This agreement expands our license relationship with Amgen on AMG 330," said John Higgins, Chief Executive Officer of Ligand Pharmaceuticals. "Ligand’s portfolio of fully-funded shots on goal continues to grow and contains a large number of Captisol-enabled drugs targeted to a number of serious diseases with unmet medical needs."
About AMG 330
AMG 330 is an anti-CD33 x anti-CD3 (BiTE) bispecific antibody construct. It is being investigated as a treatment for acute myeloid leukemia by Amgen.